PLRZ Polyrizon Ltd.
Price Chart
Executive Summary
Polyrizon Ltd. (PLRZ) announced the filing of a divisional European patent application for its Trap & Target (T&T) intranasal drug delivery platform, aimed at enhancing drug bioavailability and residence time in the nasal cavity. This follows a recent U.S. patent application and strengthens the company's IP portfolio for its two core technologies: T&T and Capture & Contain (C&C). However, the company remains in development stage with no revenue and is concurrently raising capital through a dilutive follow-on offering.
Actionable Insight
The patent filing is a positive step for IP protection but does not alter the company's fundamental risk profile. Traders should weigh this development against the ongoing dilutive capital raise and lack of revenue. Monitor for future clinical milestones or partnerships that could validate the platform's commercial potential.
Key Facts
- Polyrizon filed a divisional European patent application for its Trap & Target (T&T) intranasal drug delivery platform.
- The T&T platform aims to improve drug bioavailability, prolong residence time, prevent dripping, and enable controlled release for diverse therapeutics including corticosteroids, benzodiazepines, and naloxone.
- This filing follows a recent U.S. patent application covering both T&T and Capture & Contain (C&C) technologies.
- The company is a development-stage biotech with no current revenue, relying on R&D to advance its pipeline.
- Polyrizon is simultaneously conducting a follow-on offering to raise $2.3 million in net proceeds, which will cause shareholder dilution.
Financial Impact
No direct financial impact from patent filing; however, the concurrent $2.3 million follow-on offering will dilute existing shareholders. Offering priced at $9.00 per share and $8.99999 per pre-funded warrant.
Risk Factors
- Patent may not be granted or could be challenged; no assurance of commercial success.
- High dilution risk from recent follow-on offering in a low-market-cap shell ($26M).
- No revenue or near-term path to profitability; dependent on continued financing.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-047794 |
| Document: ea0287805-6k_polyrizon.htm | 0001213900-26-047794 |
| Document: 0001213900-26-047794-index-headers.html | 0001213900-26-047794 |
| Document: 0001213900-26-047794-index.html | 0001213900-26-047794 |
| Document: 0001213900-26-047794.txt | 0001213900-26-047794 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
6-K
| $12.66 awaiting T+5 | awaiting T+5 | — | $12.52 (−1.07%) |
|
Jun 8, 2026
1d ago
|
Press Release
| $13.22 awaiting T+5 | awaiting T+5 | — | $12.52 (−5.30%) |
|
Jun 5, 2026
4d ago
|
6-K
| $13.22 awaiting T+5 | awaiting T+5 | — | $12.52 (−5.30%) |
|
May 13, 2026
27d ago
|
6-K
| $15.18 $13.98 | ▼ −7.91% | ▼ −6.75% | $12.52 (−17.52%) |
|
May 4, 2026
5w ago
|
6-K
| $15.40 $16.12 | ▲ +4.68% | ▲ +1.74% | $12.52 (−18.70%) |
|
Apr 30, 2026
5w ago
|
F-1/A
| $16.00 $16.34 | ▲ +2.13% | ▼ −0.22% | $12.52 (−21.75%) |
|
Apr 27, 2026
6w ago
|
6-K
| $16.63 $15.40 | ▼ −7.40% | ▼ −7.80% | $12.52 (−24.71%) |
|
Apr 8, 2026
8w ago
|
6-K / PRESS-RELEASE
| $10.75 $10.94 | ▼ −1.77% | ▲ +1.42% | $12.52 (−16.47%) |
|
Apr 8, 2026
8w ago
|
424B5
| $10.75 $10.94 | ▼ −1.77% | ▲ +1.42% | $12.52 (−16.47%) |
|
Mar 30, 2026
10w ago
|
Insider Cluster
| $11.88 $11.08 | ▲ +6.73% | ▲ +11.03% | $12.52 (−5.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access